The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thro… (NCT04269954) | Clinical Trial Compass
UnknownPhase 4
The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis
China60 participantsStarted 2020-03-01
Plain-language summary
Our previous clinical case observations showed that batroxobin combined with anticoagulation therapy can improve the sinus recanalization rate in patients with CVST, shorten the hospital stay, and increase the neurological score of patients. Its main mechanism is to inhibit thrombosis after reducing fibrinogen, and to dissolve thrombus.
To further explore the safety of batroxobin combined with anticoagulation therapy for CVST, an open-label, randomized controlled (1: 1), single-center, prospective study was used. Further study on the safety and effectiveness of batroxobin combined with anticoagulation for CVST.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Cerebral venous thrombosis, confirmed by cerebral angiography (with intra-arterial contrast injection), magnetic resonance venography or computed tomographic venography.
✓. Severe form of CVST with a high chance of incomplete recovery, as defined by the presence of one or more of the following risk factors
✓. Intracerebral hemorrhagic lesion due to CVST
✓. Mental status disorder
✓. Coma (Glasgow coma scale \< 9)
✓. Thrombosis of the deep cerebral venous system
✓. Uncertainty by the treating physician if ET or standard heparin therapy is the optimal therapy for the patient.
Exclusion criteria
✕. Conditions associated with increased risk of bleeding
✕. Any thrombolytic therapy within last 7 days
✕. Cerebellar venous thrombosis with 4th ventricle compression and hydrocephalus, which requires surgery
What they're measuring
1
Percentage of Participants With Major Bleeding Event (MBE) According to International Society on Thrombosis and Haemostasis (ISTH) Criteria in Full Observation Period
✕. Contraindication for anti-coagulant or batroxobin treatment 1)documented generalized bleeding disorder 2)concurrent thrombocytopenia (\<100 x 10E9/L) 3)Fibrinogen below 100mg /dl 4)documented severe hepatic or renal dysfunction, that interferes with normal coagulation 5)uncontrolled severe hypertension (diastolic \> 120 mm Hg) 6)known recent (\< 3 months) gastrointestinal tract hemorrhage (not including hemorrhage from rectal hemorrhoids)
✕. Any known associated condition (such as terminal cancer) with a poor short term (1 year) prognosis independent of CVST
✕. Clinical and radiological signs of impending transtentorial herniation due to large space-occupying lesions (e.g. large cerebral venous infarcts or hemorrhages)
✕. Recent (\< 2 weeks) major surgical procedure (does not include lumbar puncture) or severe cranial trauma